Kempelen I, Szilárd M
Fövárosi Onkormányzat Bajcsy-Zsilinszky Kórház, Budapest.
Orv Hetil. 1995 Sep 17;136(38):2051-5.
The authors summarised pathophysiology and therapy possibility of the chronic alcoholic pancreatitis. They introduce a new product of pancreatin use for treatment of chronic alcoholic pancreatitis. The aim of this prospective study was to asses the efficacy of this new drug in the treatment of chronic alcoholic pancreatitis. The treatment was carried out by new pancreatin product containing 10,000 FIP U lipase, 9000 FIP U amylase, and 500 FIP E protease. During the study 30 patients--suffering from alcoholic pancreatitis--were treated. They received, two tablets three times daily in a period of two weeks. The following parameters were observed and compared before and after the period of treatment: complaints of the patients, the characteristics of the stool (daily weight, frequency, fat contents, consistency) the change of the body weight and degree of abdominal pain. These parameters were compared using a score-system, before and after the period of treatment. The authors could analyse the data of 21 patients. It was proved that there was a significant decrease in frequency, daily weight and fat contents of the stool and in abdominal pain. There was not significant change in the body weight. The authors concluded that this new product is a good pancreatin preparation which is useful and suitable for effective treatment of chronic alcoholic pancreatitis, if the patient keeps abstinence.
作者总结了慢性酒精性胰腺炎的病理生理学和治疗可能性。他们介绍了一种用于治疗慢性酒精性胰腺炎的新型胰酶产品。这项前瞻性研究的目的是评估这种新药治疗慢性酒精性胰腺炎的疗效。治疗采用含有10000 FIP U脂肪酶、9000 FIP U淀粉酶和500 FIP E蛋白酶的新型胰酶产品进行。在研究期间，对30例患有酒精性胰腺炎的患者进行了治疗。他们在两周内每天服用三次，每次两片。在治疗前后观察并比较了以下参数：患者的主诉、粪便特征（每日重量、频率、脂肪含量、稠度）、体重变化和腹痛程度。在治疗前后，使用评分系统对这些参数进行了比较。作者能够分析21例患者的数据。结果证明，粪便的频率、每日重量和脂肪含量以及腹痛均有显著下降。体重没有显著变化。作者得出结论，这种新产品是一种很好的胰酶制剂，如果患者戒酒，它对有效治疗慢性酒精性胰腺炎是有用且合适的。
